A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease
Status:
Recruiting
Trial end date:
2025-03-07
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on
clinical decline as measured by the Integrated Alzheimer's Disease Rating Scale (iADRS), a
composite of cognition and function.